Center for Molecular Medicine Cologne

Florian Klein - assoc. RG 10

Antibody-mediated therapy and prevention of infectious pathogens

Introduction

Our Laboratory focuses on human immunology with a strong interest in the development of B lymphocytes and antibodies.

In particular, we are interested in the antibody response to HIV-1 and other infectious pathogens.

Our Aims

We aim to precisely understand the biology of humoral immunity and to use this knowledge to effectively prevent and treat infectious diseases.

To this end, our laboratory works with a wide range of techniques in molecular immunology and conducts clinical trials that enable us to translate our findings into clinical applications.

Our group is dedicated to provide an excellent work environment to train young scientists and for pursuing forefront and innovative research.

  1. Akkina R, Allam A, Balazs AB, Blankson JN, Burnett JC, Casares S, Garcia JV, Hasenkrug KJ, Kashanchi F, Kitchen SG, Klein F, Kumar P, Luster AD, Poluektova LY, Rao M, Sanders-Beer BE, Shultz LD, and Zack JA (2016). Improvements and limitations of humanized mouse models for hiv research: Nih/niaid "meet the experts" 2015 workshop summary. AIDS Res Hum Retroviruses 32, 109-119.
  2. Gautam R, Nishimura Y, Pegu A, Nason MC, Klein F, Gazumyan A, Golijanin J, Buckler-White A, Sadjadpour R, Wang K, Mankoff Z, Schmidt SD, Lifson JD, Mascola JR, Nussenzweig MC, and Martin MA (2016). A single injection of anti-hiv-1 antibodies protects against repeated shiv challenges. Nature 533, 105-109.
  3. Schoofs T, Klein F, Braunschweig M, Kreider EF, Feldmann A, Nogueira L, Oliveira T, Lorenzi JC, Parrish EH, Learn GH, West AP, Jr., Bjorkman PJ, Schlesinger SJ, Seaman MS, Czartoski J, McElrath MJ, Pfeifer N, Hahn BH, Caskey M, and Nussenzweig MC (2016). Hiv-1 therapy with monoclonal antibody 3bnc117 elicits host immune responses against hiv-1. Science 352, 997-1001.
  4. Caskey, M.*, Klein, F.*, Lorenzi, J.C., Seaman, M.S., West, A.P., Jr., Buckley, N., Kremer, G., Nogueira, L., Braunschweig, M., Scheid, J.F., Horwitz, J.A., Shimeliovich, I., Ben-Avraham, S., Witmer-Pack, M., Platten, M., Lehmann, C., Burke, L.A., Hawthorne, T., Gorelick, R.J., Walker, B.D., Keler, T., Gulick, R.M., Fatkenheuer, G., Schlesinger, S.J., and Nussenzweig, M.C., Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117.Nature (2015).
  5.  Klein, F., Nogueira, L., Nishimura, Y., Phad, G., West, A.P., Jr., Halper-Stromberg, A., Horwitz, J.A., Gazumyan, A., Liu, C., Eisenreich, T.R., Lehmann, C., Fatkenheuer, G., Williams, C., Shingai, M., Martin, M.A., Bjorkman, P.J., Seaman, M.S., Zolla-Pazner, S., Karlsson Hedestam, G.B., and Nussenzweig, M.C., Enhanced HIV-1 immunotherapy by commonly arising antibodies that target virus escape variants.J Exp Med.(2014).
  6. Klein, F., Mouquet, H., Dosenovic, P., Scheid, J.F., Scharf, L., and Nussenzweig, M.C., Antibodies in HIV-1 vaccine development and therapy. Science (2013).
  7. Klein, F., Diskin, R., Scheid, J.F., Gaebler, C., Mouquet, H., Georgiev, I.S., Pancera, M., Zhou, T., Incesu, R.B., Fu, B.Z., Gnanapragasam, P.N., Oliveira, T.Y., Seaman, M.S., Kwong, P.D., Bjorkman, P.J., and Nussenzweig, M.C., Somatic mutations of the immunoglobulin framework are generally required for broad and potent HIV-1 neutralization. Cell (2013).
  8. Klein, F., Halper-Stromberg, A., Horwitz, J.A., Gruell, H., Scheid, J.F., Bournazos, S., Mouquet, H., Spatz, L.A., Diskin, R., Abadir, A., Zang, T., Dorner, M., Billerbeck, E., Labitt, R.N., Gaebler, C., Marcovecchio, P.M., Incesu, R.B., Eisenreich, T.R., Bieniasz, P.D., Seaman, M.S., Bjorkman, P.J., Ravetch, J.V., Ploss, A., and Nussenzweig, M.C., HIV therapy by a combination of broadly neutralizing antibodies in humanized mice. Nature (2012).
  • Augustin M, Schommers P, Suarez I, Koehler P, Gruell H, Klein F, Maurer C, Langerbeins P, Priesner V, Schmidt-Hellerau K, Malin JJ, Stecher M, Jung N, Wiesmuller G, Meissner A, Zweigner J, Langebartels G, Kolibay F, Suarez V, Burst V, Valentin P, Schedler D, Cornely OA, Hallek M, Fatkenheuer G, Rybniker J, and Lehmann C (2020). Rapid response infrastructure for pandemic preparedness in a tertiary care hospital: lessons learned from the COVID-19 outbreak in Cologne, Germany, February to March 2020. Euro Surveill 25.
     
  • Cohen-Dvashi H, Zehner M, Ehrhardt S, Katz M, Elad N, Klein F, and Diskin R (2020). Structural Basis for a Convergent Immune Response against Ebola Virus. Cell Host Microbe 27, 418-27 e4.
     
  • Di Cristanziano V, Meyer-Schwickerath C, Eberhardt KA, Rybniker J, Heger E, Knops E, Hallek M, Klein F, Holtick U, and Jung N (2020). Detection of SARS-CoV-2 viremia before onset of COVID-19 symptoms in an allo-transplanted patient with acute leukemia. Bone marrow transplantation 10.1038/s41409-020-01059-y.
     
  • Eberhardt KA, Meyer-Schwickerath C, Heger E, Knops E, Lehmann C, Rybniker J, Schommers P, Eichenauer DA, Kurth F, Ramharter M, Kaiser R, Holtick U, Klein F, Jung N, and Di Cristanziano V (2020). RNAemia Corresponds to Disease Severity and Antibody Response in Hospitalized COVID-19 Patients. Viruses 12.
     
  • Heidepriem J, Krahling V, Dahlke C, Wolf T, Klein F, Addo MM, Becker S, and Loeffler FF (2020). Epitopes of Naturally Acquired and Vaccine-induced Anti-Ebola Virus Glycoprotein Antibodies in Single Amino Acid Resolution. Biotechnol J 10.1002/biot.202000069, e2000069.
     
  • Kreer C, Doring M, Lehnen N, Ercanoglu MS, Gieselmann L, Luca D, Jain K, Schommers P, Pfeifer N, and Klein F (2020a). openPrimeR for multiplex amplification of highly diverse templates. J Immunol Methods 480, 112752.
     
  • Kreer C, Gruell H, Mora T, Walczak AM, and Klein F (2020b). Exploiting B Cell Receptor Analyses to Inform on HIV-1 Vaccination Strategies. Vaccines (Basel) 8.
     
  • Kreer C, Zehner M, Weber T, Ercanoglu MS, Gieselmann L, Rohde C, Halwe S, Korenkov M, Schommers P, Vanshylla K, Di Cristanziano V, Janicki H, Brinker R, Ashurov A, Krahling V, Kupke A, Cohen-Dvashi H, Koch M, Eckert JM, Lederer S, Pfeifer N, Wolf T, Vehreschild MJGT, Wendtner C, Diskin R, Gruell H, Becker S, and Klein F (2020c). Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients. Cell 182, 843-+.
     
  • Luers JC, Rokohl AC, Loreck N, Wawer Matos PA, Augustin M, Dewald F, Klein F, Lehmann C, and Heindl LM (2020a). Olfactory and Gustatory Dysfunction in Coronavirus Disease 2019 (COVID-19). Clin Infect Dis 71, 2262-4.
     
  • Luers JC, Rokohl AC, Loreck N, Wawer Matos PA, Augustin M, Dewald F, Klein F, Lehmann C, and Heindl LM (2020b). Reply to Gourtsoyannis. Clin Infect Dis 10.1093/cid/ciaa693.
     
  • Niessl J, Baxter AE, Mendoza P, Jankovic M, Cohen YZ, Butler AL, Lu CL, Dube M, Shimeliovich I, Gruell H, Klein F, Caskey M, Nussenzweig MC, and Kaufmann DE (2020). Combination anti-HIV-1 antibody therapy is associated with increased virus-specific T cell immunity. Nat Med 26, 222-7.
     
  • Ramani A, Muller L, Ostermann PN, Gabriel E, Abida-Islam P, Muller-Schiffmann A, Mariappan A, Goureau O, Gruell H, Walker A, Andree M, Hauka S, Houwaart T, Dilthey A, Wohlgemuth K, Omran H, Klein F, Wieczorek D, Adams O, Timm J, Korth C, Schaal H, and Gopalakrishnan J (2020). SARS-CoV-2 targets neurons of 3D human brain organoids. EMBO J 39, e106230.
     
  • Schermer B, Fabretti F, Damagnez M, Di Cristanziano V, Heger E, Arjune S, Tanner NA, Imhof T, Koch M, Ladha A, Joung J, Gootenberg JS, Abudayyeh OO, Burst V, Zhang F, Klein F, Benzing T, and Muller RU (2020). Rapid SARS-CoV-2 testing in primary material based on a novel multiplex RT-LAMP assay. PloS one 15, e0238612.
     
  • Schommers P, Gruell H, Abernathy ME, Tran MK, Dingens AS, Gristick HB, Barnes CO, Schoofs T, Schlotz M, Vanshylla K, Kreer C, Weiland D, Holtick U, Scheid C, Valter MM, van Gils MJ, Sanders RW, Vehreschild JJ, Cornely OA, Lehmann C, Fatkenheuer G, Seaman MS, Bloom JD, Bjorkman PJ, and Klein F (2020). Restriction of HIV-1 Escape by a Highly Broad and Potent Neutralizing Antibody. Cell 180, 471-89 e22.
     
  • Stecher M, Classen A, Klein F, Lehmann C, Gruell H, Platten M, Wyen C, Behrens G, Fatkenheuer G, and Vehreschild JJ (2020). Systematic Review and Meta-analysis of Treatment Interruptions in Human Immunodeficiency Virus (HIV) Type 1-infected Patients Receiving Antiretroviral Therapy: Implications for Future HIV Cure Trials. Clin Infect Dis 70, 1406-17.
     
  • Theobald SJ, Kreer C, Khailaie S, Bonifacius A, Eiz-Vesper B, Figueiredo C, Mach M, Backovic M, Ballmaier M, Koenig J, Olbrich H, Schneider A, Volk V, Danisch S, Gieselmann L, Ercanoglu MS, Messerle M, Kaisenberg CV, Witte T, Klawonn F, Meyer-Hermann M, Klein F, and Stripecke R (2020). Repertoire characterization and validation of gB-specific human IgGs directly cloned from humanized mice vaccinated with dendritic cells and protected against HCMV. PLoS pathogens 16, e1008560.
     
  • Zehner M, and Klein F (2020). Antibody Teamwork against Ebola Virus Disease. Immunity 52, 217-9.
Prof. Dr. Florian Klein CMMC Cologne
Prof. Dr. Florian Klein

Institute of Virology / RG location - CMMC Building

assoc. CMMC Research Group

Executive Board Member

+49 221 478 89693

+49 221 478 3904

Institute of Virology / RG location - CMMC Building

Robert-Koch-Str. 21

50931 Cologne

https://klein-lab.de/

CMMC Profile Page

Curriculum Vitae (CV)

Publications - Florian Klein

Link to PubMed